

#### Source

Anti-Bevacizumab Antibody (AY9) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

Clone

AY9

**Species** 

Mouse

**Isotype** 

Mouse IgG1/kappa

**Antibody Type** 

Hybridoma Monoclonal

Reactivity

Human

Immunogen

Bevacizumab.

**Specificity** 

Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.

Usage

### **Application**

Application	Recommended

ELISA

20-10000 ng/mL

### **Purity**

>95% as determined by SDS-PAGE.

#### **Purification**

Protein A purified/ Protein G purified

#### **Formulation**

Lyophilized from 0.22  $\mu m$  filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

## Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

# SDS-PAGE




Anti-Bevacizumab Antibody (AY9) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein






is greater than 95%.

#### **Bioactivity-ELISA**




Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 1  $\mu$ g/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9, 10% human serum) and then add biotinylated bevacizumab at 5  $\mu$ g/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9 ng/mL (QC tested).




Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 62%.

## **Bioactivity-MSD**



Anti-Bevacizumab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Bevacizumab at 5

## Determination of Anti-Bevacizumab Antibodies Specificity



Demonstration of the specificity of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) to the bevacizumab.




# Anti-Bevacizumab Antibody (AY9) (recommended for ADA assay)





 $\mu$ g/mL, SULFO-Bevacizumab at 5  $\mu$ g/mL and increasing concentrations of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.

# **Bioactivity-SPR**



Anti-Bevacizumab Antibody (AY9) (mouse IgG1, Cat. No. BEB-Y9) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 1.92 nM.

### Background

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

### **Clinical and Translational Updates**

